ClinicalTrials.gg
RecruitingNCT07819097Updated Oct 9, 2026

A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults

A Phase 3 interventional study of RSVpreF and Placebo in Adult and Healthy Participants, sponsored by Pfizer. Recruiting at 15 sites in 2 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn about the safety, tolerability, and immune response of the RSVpreF vaccine in healthy older adults.

Participants will take part in this study for about 6 months.

The study will include people in China and the United States. In China, participants will receive either RSVpreF or placebo. A placebo is a dummy vaccine with no active ingredient, but it looks just like the vaccine being studied. In the United States, all participants will receive RSVpreF.

Researchers will check for any reactions. They will also check blood test results to learn how the body responds to the vaccine.

The main questions the study aims to answer are:

  • What local reactions and systemic events (body-wide symptoms) do participants have after a RSVpreF vaccination?
  • What medical problems do participants have after a RSVpreF vaccination?
  • Researchers will compare antibody levels from blood tests between the China cohort and the US cohort. An antibody is a substance in the body that try to fight off an infection or foreign substance.

Participants will:

  • Have a screening visit to make sure they qualify for the study (participants in China will have this visit before the day of vaccination)
  • Receive the RSVpreF vaccination (or a placebo injection if in the China cohort) once at Visit 1.
  • Have a telephone or clinic visit 1 week later to assess local reactions and systemic events.
  • Have a clinic visit a month after vaccination for a checkup and tests.
  • Have a telephone or clinic visit 6 months after vaccination for a health check.
  • Have a blood test at screening (if in the China cohort only), on the day of vaccination and 1 month after vaccination.
02

Conditions studied

  • Adult
  • Healthy Participants

Keywords

  • RSV vaccine
  • Respiratory Syncytial Virus (RSV)
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria

  • Participants 60 years of age or older at enrolment.
  • Healthy participants, or participants with stable long-term medical conditions, if the investigator decides they can take part.
  • Adults who can walk and live in the community or in assisted-living/long-term care settings with minimal help.
  • Participants who can give signed and follow study visits and procedures, including the 7-day electronic diary and blood tests.

Key Exclusion Criteria

  • Confirmed RSV infection 180 days or less before study vaccination.
  • Any past history of Guillain-Barré syndrome.
  • Severe reaction to a vaccine or severe allergy to a study vaccine component or related vaccine.
  • Serious or unstable medical condition that the investigator believes makes the study unsafe.
  • status, based on medical history and/or examination.
  • Previous receipt of any licensed or RSV vaccine or RSV preventive monoclonal antibody, or planned receipt during the study.

Please refer to the study contact for further eligibility details Contacts/Locations Central Contact Person: Pfizer CT.gov Call Center Telephone: 1-800-718-1021 Email: ClinicalTrials.gov_Inquiries@pfizer.com

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Placebo comparator
    China Placebo

    Single dose, Placebo vaccine

    Other: Placebo

  • Active comparator
    China RSVpreF

    Single dose, RSVpreF vaccine

    Biological: RSVpreF

  • Active comparator
    US RSVpreF

    Single dose, RSVpreF vaccine

    Biological: RSVpreF

Interventions

  • BiologicalRSVpreF

    Single Dose

  • OtherPlacebo

    Single Dose

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting local reactions: pain at the injection site, redness, and swelling

    Time frame: Within 7 days after vaccination

  2. Percentage of participants reporting systemic events: fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain, and joint pain

    Time frame: Within 7 days after vaccination

  3. Percentage of participants reporting adverse events (AEs)

    Time frame: Within 1 month after vaccination

  4. Percentage of participants reporting serious adverse events (SAEs)

    Time frame: Through 6 months after vaccination

  5. Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)

    Time frame: Through 6 months after vaccination

  6. RSV A and RSV B neutralizing antibody levels before vaccination and 1 month after vaccination

    Time frame: Before vaccination and 1 month after vaccination

  7. Geometric mean fold rise in RSV A and RSV B neutralizing antibody levels from before vaccination to 1 month after vaccination

    Time frame: Before vaccination to 1 month after vaccination

Secondary outcomes

  1. Seroresponse rate for RSV A and RSV B neutralizing antibody levels

    Time frame: 1 month after vaccination

07

Study locations

1 of 15 sites recruiting
  • Headlands Research - Scottsdale
    Scottsdale, Arizona 85260, United States
    Not yet recruiting
  • Orange County Research Center
    Lake Forest, California 92630, United States
    Not yet recruiting
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
    Not yet recruiting
  • Clinical Research Consulting, LLC
    Milford, Connecticut 06460, United States
    Not yet recruiting
  • George Washington University
    Washington D.C., District of Columbia 20037, United States
    Not yet recruiting
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
    Not yet recruiting
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
    Not yet recruiting
  • IMA Clinical Research Warren
    Warren Township, New Jersey 07059, United States
    Not yet recruiting
  • Remington-Davis, Inc
    Columbus, Ohio 43215, United States
    Not yet recruiting
  • DM Clinical Research - Philadelphia
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
  • J. Lewis Research, Inc. / Foothill Family Clinic Draper
    Draper, Utah 84020, United States
    Not yet recruiting
  • J. Lewis Research, Inc. / Jordan River Family Medicine
    South Jordan, Utah 84095, United States
    Not yet recruiting
  • Charlottesville Medical Research Center, LLC
    Charlottesville, Virginia 22911, United States
    Not yet recruiting
  • Clinical Research Partners, LLC
    Richmond, Virginia 23226, United States
    Not yet recruiting
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200040, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 14, 2026
StartActual
Sep 9, 2026
Primary completionEst.
May 16, 2027
CompletionEst.
May 16, 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
9 sites added. 6 sites changed recruiting status (5 now not yet recruiting, 1 now recruiting)
Show 6 sites
  • Clinical Research Consulting, LLC · Milford, United Statesno status→Not yet recruiting
  • Remington-Davis, Inc · Columbus, United Statesno status→Not yet recruiting
  • DM Clinical Research - Philadelphia · Philadelphia, United Statesno status→Not yet recruiting
  • J. Lewis Research, Inc. / Foothill Family Clinic Draper · Draper, United Statesno status→Not yet recruiting
  • Clinical Research Partners, LLC · Richmond, United Statesno status→Not yet recruiting
  • Huashan Hospital Fudan University · Shanghai, Chinano status→Recruiting
Show 9 added (9 United States)
  • Headlands Research - Scottsdale · Scottsdale, United States
  • Orange County Research Center · Lake Forest, United States
  • Artemis Institute for Clinical Research · Riverside, United States
  • George Washington University · Washington D.C., United States
  • Solaris Clinical Research · Meridian, United States
  • MediSphere Medical Research Center, LLC · Evansville, United States
  • IMA Clinical Research Warren · Warren Township, United States
  • J. Lewis Research, Inc. / Jordan River Family Medicine · South Jordan, United States
  • Charlottesville Medical Research Center, LLC · Charlottesville, United States
Oct 9, 2026
Primary completion
May 15, 2027→May 16, 2027
Oct 9, 2026
Study completion
May 15, 2027→May 16, 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    9 sites added. 6 sites changed recruiting status (5 now not yet recruiting, 1 now recruiting)
    Show 6 sites
    • Clinical Research Consulting, LLC · Milford, United Statesno status→Not yet recruiting
    • Remington-Davis, Inc · Columbus, United Statesno status→Not yet recruiting
    • DM Clinical Research - Philadelphia · Philadelphia, United Statesno status→Not yet recruiting
    • J. Lewis Research, Inc. / Foothill Family Clinic Draper · Draper, United Statesno status→Not yet recruiting
    • Clinical Research Partners, LLC · Richmond, United Statesno status→Not yet recruiting
    • Huashan Hospital Fudan University · Shanghai, Chinano status→Recruiting
    Show 9 added (9 United States)
    • Headlands Research - Scottsdale · Scottsdale, United States
    • Orange County Research Center · Lake Forest, United States
    • Artemis Institute for Clinical Research · Riverside, United States
    • George Washington University · Washington D.C., United States
    • Solaris Clinical Research · Meridian, United States
    • MediSphere Medical Research Center, LLC · Evansville, United States
    • IMA Clinical Research Warren · Warren Township, United States
    • J. Lewis Research, Inc. / Jordan River Family Medicine · South Jordan, United States
    • Charlottesville Medical Research Center, LLC · Charlottesville, United States
    Primary completion May 15, 2027→May 16, 2027
    Study completion May 15, 2027→May 16, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07819097
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 14, 2026
Start date
Sep 9, 2026
Primary completion
May 16, 2027 (estimated)
Completion
May 16, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrysvo

Start the discussion